Aim: Severe neurological and endocrine toxicities are well recognised adverse events of immune checkpoint inhibitors. However, the underlying pathophysiology is poorly understood, and classical circulating markers are often non-informative, making it difficult to obtain a precise diagnosis and to initiate timely and effective treatment. Here we investigated immune-modulating activity in the plasma of a mesothelioma patient who developed fatal neuroendocrine toxicity characterised by insulin-dependent diabetes, hypophisitis and a myasthenia-like syndrome while on treatment with the dual PD1 and TIM3 blockade. Methods: We used an in vitro functional assay for unbiased detection of plasma dendritic cell–modulating activity, followed by cytokine quantification by the Cytokine Bead Array. Results: Immunosuppressive treatment as per established guidelines could not prevent the fatal outcome. Patient's plasma contained a dendritic cell–stimulating activity that induced specific markers (CD25+) compatible with T-helper 17 stimulation. Consistently, elevated levels of interleukin 17 (IL17A), but no other cytokines, were identified in the patient's plasma but not in controls (healthy volunteers and patients treated with immunotherapy without neuroendocrine toxicities). Conclusion: If confirmed in larger series, these data suggest IL17 as a candidate diagnostic and therapeutic target in the management of high-grade neuroendocrine immune-related adverse events.

Evidence for interleukin 17 involvement in severe immune-related neuroendocrine toxicity / L. Mazzarella, S. Giugliano, P. D'Amico, C. Belli, B.A. Duso, M. Rescigno, G. Curigliano. - In: EUROPEAN JOURNAL OF CANCER. - ISSN 0959-8049. - 141(2020), pp. 218-224. [10.1016/j.ejca.2020.10.006]

Evidence for interleukin 17 involvement in severe immune-related neuroendocrine toxicity

L. Mazzarella
;
G. Curigliano
Conceptualization
2020

Abstract

Aim: Severe neurological and endocrine toxicities are well recognised adverse events of immune checkpoint inhibitors. However, the underlying pathophysiology is poorly understood, and classical circulating markers are often non-informative, making it difficult to obtain a precise diagnosis and to initiate timely and effective treatment. Here we investigated immune-modulating activity in the plasma of a mesothelioma patient who developed fatal neuroendocrine toxicity characterised by insulin-dependent diabetes, hypophisitis and a myasthenia-like syndrome while on treatment with the dual PD1 and TIM3 blockade. Methods: We used an in vitro functional assay for unbiased detection of plasma dendritic cell–modulating activity, followed by cytokine quantification by the Cytokine Bead Array. Results: Immunosuppressive treatment as per established guidelines could not prevent the fatal outcome. Patient's plasma contained a dendritic cell–stimulating activity that induced specific markers (CD25+) compatible with T-helper 17 stimulation. Consistently, elevated levels of interleukin 17 (IL17A), but no other cytokines, were identified in the patient's plasma but not in controls (healthy volunteers and patients treated with immunotherapy without neuroendocrine toxicities). Conclusion: If confirmed in larger series, these data suggest IL17 as a candidate diagnostic and therapeutic target in the management of high-grade neuroendocrine immune-related adverse events.
IL17; Immune-related adverse event; Immunotherapy; Myasthenia gravis; PD1; Antineoplastic Agents, Immunological; Autoimmune Hypophysitis; Diabetes Mellitus, Type 1; Fatal Outcome; Humans; Immune Checkpoint Inhibitors; Immunotherapy; Interleukin-17; Male; Mesothelioma, Malignant; Middle Aged; Myasthenia Gravis
Settore MED/06 - Oncologia Medica
Article (author)
File in questo prodotto:
File Dimensione Formato  
Interleukin 17 and Curigliano 2020.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 759.28 kB
Formato Adobe PDF
759.28 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/824912
Citazioni
  • ???jsp.display-item.citation.pmc??? 4
  • Scopus 7
  • ???jsp.display-item.citation.isi??? 7
social impact